Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide

Journal of Cardiovascular Pharmacology
J DingemanseM Stabl

Abstract

Irreversible, nonselective monoamine oxidase (MAO) inhibitors have been reported adversely to interact with indirectly acting sympathomimetic amines present in many cough and cold medicines. This study investigated the safety and tolerability of concomitant administration to 12 healthy subjects of both genders (aged 19-36 years) of ephedrine and moclobemide, a reversible MAO-A inhibitor. A 2-day, randomized, crossover administration of placebo or ephedrine (two doses of 50 mg with a 4-h interval) was followed by 9 days open-label dosing with moclobemide, 300 mg b.i.d.. On the last 2 days of moclobemide dosing, the randomized crossover treatment of ephedrine and placebo was repeated. No subject was withdrawn from the study for tolerability reasons. Moclobemide treatment, however, increased the incidence of adverse events elicited by ephedrine, particularly palpitations and headache. The pharmacodynamic interaction between the two drugs was quantified by calculation of the area under the effect-time course (AUE) for systolic (SBP) and diastolic blood pressure (DBP) and heart rate (HR). The difference in AUE between monotreatment with ephedrine and placebo was statistically significant for all three vital signs. Moclobemide potent...Continue Reading

References

Nov 1, 1992·The Australian Nurses' Journal·S Ewart
Aug 29, 1991·The New England Journal of Medicine·W Z PotterH Manji
Feb 1, 1991·Journal of Clinical Psychopharmacology·B Blackwell
Jan 1, 1990·Acta Psychiatrica Scandinavica. Supplementum·R ZimmerS Gasic
Jan 1, 1990·Acta Psychiatrica Scandinavica. Supplementum·R JauchT W Guentert
Jan 1, 1989·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·D G Wells, A R Bjorksten
Dec 1, 1989·Postgraduate Medicine·L M Prisant, A A Carr
Feb 10, 1973·British Medical Journal·A J BoakesB N Prichard
Apr 1, 1980·British Journal of Clinical Pharmacology·D W EmpeyD T Hughes
Jan 1, 1982·European Journal of Clinical Pharmacology·P R Bieck, K H Antonin
Oct 14, 1995·Lancet·D M Coulter, P I Pillans
Jan 1, 1994·Clinical Neuropharmacology·E MollR Amrein
Nov 1, 1995·Clinical Pharmacokinetics·M Mayersohn, T W Guentert

❮ Previous
Next ❯

Citations

Oct 25, 2011·Annales Françaises D'anesthèsie Et De Rèanimation·B RozecY Blanloeil
Apr 20, 2004·British Journal of Clinical Pharmacology·Adam M PerskyKim L R Brouwer
May 4, 2021·Current Opinion in Anaesthesiology·David B Guthrie, Deborah C Richman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.